VI 25 mcg OD (N = 115) | SAL 50 mcg BD (N = 116) | Placebo (N = 116) | Total (N = 347) | |
---|---|---|---|---|
Age, years | 41.0 (17.81) | 41.1 (16.84) | 41.7 (16.64) | 41.3 (17.06) |
Female sex, n (%) | 68 (59) | 77 (66) | 59 (51) | 204 (59) |
Duration of asthma, years | 17.61 (13.54) | 19.41 (14.87) | 18.43 (13.33) | 18.49 (13.91) |
Screening pre-bronchodilator FEV1 (ml) | 2133 (631.4) | 2078 (591.7) | 2204 (653.0) | 2139 (626.2) |
Screening % predicted FEV1 | 66.6 (12.84) | 65.8 (12.72) | 65.9 (12.03) | 66.1 (12.50) |
Screening % reversibility FEV1 | 28.2 (16.36) | 26.2 (13.82) | 30.0 (16.58) | 28.1 (15.67) |
Screening absolute FEV1 reversibility (ml) | 577.1 (344.79) | 533.7 (313.85) | 650.6 (383.34) | 587.2 (350.84) |
Baseline pre-dose FEV1 (ml) | 2264 (619.7) | 2174 (587.7) | 2250 (704.0) | 2229 (637.9) |
Baseline rescue-free 24-hour periods (%) | 7.5 (19.49) | 8.0 (19.48) | 4.9 (16.21) | NA |
Baseline symptom-free periods (%) | 5.1 (15.79) | 6.0 (16.20) | 2.4 (11.11) | NA |